One-Third of Women Treated for Breast Cancer Not Getting Followup Imaging
Madison, Wisconsin - An annual mammogram is recommended after treatment for breast cancer, but nearly one-third of women diagnosed with breast cancer aren’t receiving this followup exam, according to new findings presented at the 2016 Annual Clinical Congress of the American College of Surgeons.
While previous studies on Medicare patients suggest that surveillance imaging is underused, the use of mammography in a broad range of women diagnosed with breast cancer is unknown, as is the role of surveillance magnetic resonance imaging (MRI).
For this study, Dr. Caprice C. Greenberg of the University of Wisconsin School of Medicine and Public Health (SMPH) and colleagues assessed the receipt of surveillance breast MRI and mammography in 9,622 women who underwent a surgical procedure to treat Stage II and III breast cancer from 2006 through 2007 with data collected from the National Cancer Database (NCDB).
The NCDB is jointly sponsored by the American College of Surgeons and the American Cancer Society. Greenberg is professor of surgery and Morgridge Distinguished Chair in Health Services Research at the UW School of Medicine and Public Health.
The researchers assessed imaging, cancer recurrence, new cancer, and death from the time of treatment and for five years after diagnosis. Next, they collected additional data on the reason for imaging (diagnostic evaluation of a new sign or symptom or surveillance imaging in the absence of signs and symptoms). Fifty percent of the study population was under age 60.
“Most of what we know about breast imaging comes from small studies or from Medicare data, a population that is 65 years old and older,” said Greenberg, who is also the director of the Wisconsin Surgical Outcomes Research Program (WiSOR). “This study is the first to look at a large, multi-institutional population of patients across all age groups.”
According to study results, annual receipt of surveillance breast imaging declined 8 percent from the first year (66 percent) to the fourth year (58 percent). Study findings also indicate that among women who received surveillance imaging, only about 10 percent received breast MRIs.
“The most striking finding is that over 30 percent of women don’t even get surveillance breast imaging in the first place,” Greenberg said. “For some reason, we are not plugging them into followup surveillance from the outset. We also see that there are some disparities in the use of mammograms after the treatment of breast cancer.”
The study shows that factors associated with not receiving breast imaging include younger age, black race, public or no insurance, worse health, more advanced cancers, receipt of excision alone or mastectomy (versus lumpectomy with radiation), and lack of systemic therapy.
“The critical story here is that if women start off their followup care receiving guideline-recommended imaging, they’re likely to continue to receive that imaging over time. Women who don’t receive imaging in that first followup year are not likely to receive recommended surveillance breast imaging longer-term,” said study co-author Jessica R. Schumacher, PhD, an associate scientist at WiSOR. “The bulk of the disparity seems to occur in that first year of follow up, so it’s really important to think about what we might be able to do in that timeframe to make sure women get guideline-recommended breast imaging.”
In looking at the use of both MRI and mammography, the researchers found that receipt of mammography was not influenced by where a woman received her care, but MRI was.
“This finding shows that the problem is probably at the patient population level, as opposed to what we often see, which is that there is great variation in utilization of care across hospitals,” Greenberg said. “MRI is a discretionary modality and not currently recommended in guidelines for routine surveillance following breast cancer treatment, but helpful and appropriate in certain patients. Therefore, it’s much more vulnerable to local practice patterns, whereas mammogram is something we all know is effective and, in general, the likelihood of getting it doesn’t matter where you receive your care.”
Understanding why cancer survivors aren’t receiving surveillance breast imaging and the consequences of this underuse should be a high priority, the researchers note.
“We need to recognize the fact that right now we are putting out more and more guidelines to help standardize care and to ensure patients get high quality care, but the guidelines that are already out there have been available for a long time. So I think it’s important for health care practitioners to realize that it’s not enough to just put information out there. Instead, we have to be more thoughtful about how we implement what we recommend into the actual care process,” Greenberg said.
The UW Health Breast Center provides patients with survivorship care plans which outline the steps for surveillance mammograms and clinical followup in the years after a breast cancer diagnosis. Individuals can also choose to have a “transition visit” which allows a patient to sit down with a survivorship expert to outline the best plan for followup.
Greenberg notes that standardizing care plans after treatment and using a team approach to ensure surveillance guidelines are followed is one approach to making sure individuals get the followup care they need after a cancer diagnosis.
Other study participants include:
- Taiwo Adesoye, MD, MPH
- Heather B. Neuman, MD, FACS
- Stephen B. Edge, MD, FACS
- Daniel P. McKellar, MD, FACS
- David P. Winchester, MD, FACS
- Amanda B. Francescatti, MS
“FACS” designates that a surgeon is Fellow of the American College of Surgeons.
Research reported in this press release was fully funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (CE-1304-6543). This publication was further made possible by CTSA Grant Numbers UL1 TR000135 and KL2TR000136-09 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH); the National Cancer Institute (NCI) of the NIH under award numbers U10CA031946, U10CA033601, U10CA180821, and U10CA180882 (to the Alliance for Clinical Trials in Oncology), U10CA076001 (to the American College of Surgeons Oncology Group), and U10CA025224 (to the North Central Cancer Oncology Group).
Date Published: 10/20/2016